Context Introduction of novel agents for the management of advanced prostate cancer
provides a range of treatment options with notable benefits for men with metastatic castration …

Despite many recent advances in the therapy for metastatic castration-resistant prostate
cancer (mCRPC), the disease remains incurable, although men suffering from this disease …

Background There is an urgent need to identify biomarkers to guide personalized therapy in
castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen …

Small interfering RNA (siRNA) is emerging as a novel therapeutic for treating various
diseases, provided a safe and efficient delivery is available. In particular, specific delivery to …

Activation of endoplasmic reticulum (ER) stress/the unfolded protein response (UPR) has
been linked to cancer, but the molecular mechanisms are poorly understood and there is a …

Context For more precise, personalized care in prostate cancer (PC), a new classification
based on molecular features relevant for prognostication and treatment stratification is …

Metastatic prostate cancer patients present in two ways—with already disseminated disease
at the time of presentation or with disease recurrence after definitive local therapy. Androgen …

Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses
considerable therapeutic challenges. Recent genetic and technological advances have …

The treatment landscape of advanced prostate cancer has widely expanded over the past
years with androgen receptor signaling inhibitors (ARSIs) and taxane chemotherapy moving …

Background We previously showed that pretreatment detection of androgen receptor splice
variant-7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant …